Drugs / Levocloperastine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07017335 | Jun → Jul 2025 | — | Pharmbio Korea Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Levocloperastine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07017335 ↗ |
| Known as | R1_PBK_M2301 | “R1_PBK_M2301(Levocloperastine 60mg)” NCT07017335 ↗ |
| Route | Oral | “It is administered orally” NCT07017335 ↗ |